| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthesized peptide derived from human Phospho-PDGF Receptor beta / CD140b (Y1021) was used as the immunogen for the Phospho-PDGF Receptor beta (Tyr1021) antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Phospho-PDGF Receptor beta (Tyr1021) Antibody / CD140b is a anti-PDGF (phospho-Tyr1021) Rabbit antibody Recombinant Rabbit Monoclonal clone 32P59 supplied in Liquid format. Recommended for workflows such as Western blot (WB) with listed reactivity in Mouse.
Key elements and design rationale
- Target: PDGF (phospho site: Tyr1021)
- Antibody details: Rabbit, Recombinant Rabbit Monoclonal, clone 32P59, isotype Rabbit IgG
- Format: Liquid
- Applications (as listed): WB
Biological background
Phospho-PDGF Receptor beta (Tyr1021) antibody is widely applied in cancer research, vascular biology, and fibrosis studies. By detecting phosphorylation at Tyr1021, researchers can evaluate receptor activation and downstream signaling status in diverse contexts. This site specific phosphorylation links PDGFR beta to phosphoinositide hydrolysis, calcium mobilization, and mitogenic signaling.
Western blot assays distinguish phosphorylated PDGFR beta from unphosphorylated receptor, immunohistochemistry maps receptor activation in tumor vasculature and fibrotic tissues, and immunofluorescence highlights receptor localization at the plasma membrane. These assays provide direct evidence of receptor signaling in situ.
Dysregulation of PDGFR beta signaling contributes to cancers, vascular malformations, and fibrotic disease. Activating mutations and gene fusions involving PDGFRB drive leukemias and solid tumors. Excessive phosphorylation promotes pathological vessel growth and fibrosis. Phospho-PDGF Receptor beta (Tyr1021) antibody supports mechanistic studies and translational research into targeted therapies such as tyrosine kinase inhibitors. Measuring Tyr1021 phosphorylation also provides pharmacodynamic biomarkers for drug development.
Phospho-PDGF Receptor beta (Tyr1021) antibody from
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Quantifying post-translational regulation (including phosphorylation) alongside total protein levels.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Phospho-site readouts are condition-dependent and are often compared to total target levels when available.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Monoclonal antibodies provide a defined epitope recognition profile that can support consistent comparisons across experiments.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
